The mechanism of action
of TransCyte will first be presented by a series of schematic drawings prior
to presentation of clinical use. The schemas describe the current view as to
how Transcyte closes the wound and optimizes healing.
Mid Dermal (2 degree) Burn
Mid-Dermal Burn Injury
(Debrided to viable wound
bed)
The area of coagulation or
eschar has been completely removed exposing a viable but injured wound surface
(zone of injury) which can deepen. The surface itself has an increased content
of fibrin produced by activation of the clotting cascade and fibronectin
produced by the dermal cells. There is also evidence of the onset of
inflammation with vasodilation, increased neutrophils and macrophages.
The wound surface also has increased proteolytic activity which if
persistent can denature new tissue formation and growth factors.
WOUND CLOSURE USING
TRANSCYTE
The Transcyte is
shown ready to be applied to the clean wound surface. The outer synthetic
layer (knitted nylon) protects the wound surface from environmental insults.
The inner bioactive membrane is composed mainly of human fibronectin and collagen
Type I which will produce a contact adherence to the wound surface. These
elements and the other components of the inner membrane are produced by human
fibroblasts.
TRANSCYTE IN PLACE
TRANSCYTE REMOVED - HEALED MID-DERMAL BURN
A schematic drawing of a healed wound is shown after
removal of Transcyte.
